Insight

Photo of Edward Cliff from hmpgloballearningnetwork.com

Jul 27, 2024, 14:57

Edward Cliff: The development and clinical trial design of T-cell lymphoma drugs pralatrexate and belinostat

Edward Cliff, Haematology Registrar at Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, shared a post on X about a recent paper titled “US Food and Drug Administration’s Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell Lymphoma” published in Journal of Clinical Oncology.

Authors: Edward R. Scheffer Cliff, David A. Russler-Germain, C. Joseph Ross Daval and Aaron S. Kesselheim.

“In Journal of Clinical Oncology we review the development and clinical trial design of T-cell lymphoma drugs pralatrexate and belinostat, and discuss strategies for FDA Oncology to deal with delayed confirmatory clinical trials.

Read here.”

Source: Edward Cliff/X

Aaron S. Kesselheim belinostat C. Joseph Ross Daval cancer David A. Russler-Germain Edward Cliff FDA Oncology Journal of Clinical Oncology OncoDaily Oncology Peter MacCallum Cancer Centre pralatrexate T-cell lymphoma The Royal Melbourne Hospital

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage